Neomatrix Biotech (Italy)
Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies (read more) Neomatrix presenting a Poster at SITC’s 39th Annual Meeting, the leading member-driven organization focused on cancer immunotherapy.
Basic Information
- Category: business
- Website: https://www.neomatrixbiotech.com
Documented Facts
- Email: info@neomatrixbiotech.com (No linked source recorded for this statement.)
Evidence and Sources
- Neomatrix Biotech (Italy) — Official Site (official)
- Neomatrix Biotech (Italy) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Neomatrix Biotech (Italy).
- Canonical profile: https://brandsource.ai/brands/neomatrix-biotech-italy
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/neomatrix-biotech-italy/json-ld
- Citation profile API: https://brandsource.ai/api/brands/neomatrix-biotech-italy/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies (read more) Neomatrix presenting a Poster at SITC’s 39th Annual Meeting, the leading member-driven organization focused on cancer immunotherapy.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.